• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 153

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

Reunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange...

PT347 – Christopher Koddermann – Rescheduling Psilocybin, Patents and IP, and...

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business...

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction...

atai Life Sciences Secures Term Loan Facility for up to $175...

Field Trip Announces Closing of Plan of Arrangement and $19.9 Million...

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support...

Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed...

1...152153154...303Page 153 of 303

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©